US equities |
MU $1,083.00 ▲+3.58% NVDA $236.85 ▼-1.00% SNDK $1,704.46 ▲+2.65% SPCX $167.31 ▼-2.68% AMD $640.58 ▼-1.36% TSLA $377.24 ▼-0.90% INTC $112.45 ▼-0.04% AAPL $337.10 ▲+1.04%
FinancialContent

Articles published by Savara Inc.

< Previous 1 2 3 4 5 Next >
News headline image
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Chief Financial and Administrative Officer Transition
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Reports First Quarter Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Participation in 2026 Citizens Life Sciences Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
From Savara Inc.
Via Business Wire
Tickers SVRA
News headline image
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
From Savara Inc.
Via Business Wire
Tickers SVRA
< Previous 1 2 3 4 5 Next >